NASDAQ · ORIC
ORIC Pharmaceuticals, Inc.
$8.99-$0.31 (-3.33%)
ORIC Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.76% below the high.
Loading market information…
OTC · INTI · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Inhibitor Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.58% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Inhibitor Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida, is a pharmaceutical development enterprise. The company is dedicated to inventing and commercializing medical treatments for patients in the United States who suffer from various cancerous and non-cancerous cell proliferation conditions. A primary focus of their work involves advancing SUBA-Itraconazole, an oral variant of the drug itraconazole, for therapeutic applications in prostate and lung cancers. Furthermore, Inhibitor Therapeutics, Inc. has successfully completed a positive Phase 2b clinical trial for SUBA-Itraconazole in the management of basal cell carcinoma nevus syndrome. The organization was previously known as HedgePath Pharmaceuticals, Inc. until its name was officially changed in August 2019.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:32 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$8.99-$0.31 (-3.33%)
ORIC Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.76% below the high.
$15.95+$0.22 (+1.4%)
ArriVent BioPharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.48% below the high.
$0.91+$0.01 (+1.6%)
Cardiff Oncology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.45% below the high.
$0.43-$0.01 (-3.15%)
Oncolytics Biotech Inc.’s quoted price sits in the lower half of its reported 52-week range, 67.1% below the high.
$2.23-$0.14 (-5.91%)
Atossa Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.98% below the high.
$0.89-$0.06 (-6.32%)
Allarity Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.63% below the high.
$8.72+$0.39 (+4.68%)
Kazia Therapeutics Ltd ADR’s quoted price sits in the lower half of its reported 52-week range, 49.89% below the high.
$0.02+$0.00 (+17.65%)
Oncotelic Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.82% below the high.
